Ramy Farid, Ph.D.

President and Chief Executive Officer at Schrodinger

Board

Since January 2017

Age

59 years

Education

Holds a B.S. in Chemistry from the University of Rochester, a Ph.D. in Chemistry from the California Institute of Technology, and completed a National Institutes of Health postdoctoral fellowship in the Department of Biochemistry and Biophysics at the University of Pennsylvania.

Tenure

Joined in 2002 as a product manager and held positions including Vice President, Senior Vice President, President since January 2008, and Chief Executive Officer since January 2017.

Also at Schrodinger

GPM

Geoffrey Porges, MBBS

Executive Vice President and Chief Financial Officer

MDM

Margaret Dugan, M.D.

Chief Medical Officer

Patrick Lorton

Chief Operating Officer, Software

About

Dr. Farid has built a distinguished career bridging scientific expertise with strategic leadership in the biotechnology field. His early academic accomplishments and postdoctoral experience paved the way for an impactful career that began in academia and evolved in industry, demonstrating his commitment to advancing science and innovation.

Since his entry into the company in 2002, he quickly advanced through various key roles, contributing significantly to the company’s growth. His progression from product manager to vice president, and later senior vice president, set the stage for his pivotal appointments as President and, subsequently, Chief Executive Officer, underscoring his enduring influence on the company's strategic direction.

Beyond his executive responsibilities, Dr. Farid also lends his expertise to several board roles, enhancing the company’s involvement and impact in the broader biotechnology arena. His participation in multiple biotech initiatives reflects his ability to translate scientific innovation into successful business ventures, fostering industry advancements and collaborative partnerships.

$SDGR Performance Under Ramy Farid, Ph.D.

Past Roles

Organization	Role	Date Range	Details
Schrödinger, Inc.	Senior Vice President	January 2005 to December 2007	Held before becoming President and CEO
Schrödinger, Inc.	Vice President, Scientific Development and Product Management	January 2003 to December 2004	Held before becoming President and CEO
Schrödinger, Inc.	Product Manager	January 2002 to December 2002	Held before becoming President and CEO
Rutgers University	Assistant Professor, Chemistry Department	N/A	Position held prior to joining Schrödinger, Inc.
University of Pennsylvania	NIH Postdoctoral Fellow, Department of Biochemistry and Biophysics	N/A	Position held prior to joining Schrödinger, Inc.

External Roles

Organization	Role	Date Range	Details
Structure Therapeutics, Inc.	Board of Directors	Current	Publicly traded biopharmaceutical company

Fixed Compensation

Data from FY 2024

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$704,080	Annual	4% increase over 2023
Target Cash Incentive Award	65% of Base Salary	Annual payout in early 2025	5% increase over 2023; based on performance metrics similar to 2023

Performance Compensation

Data from FY 2024

Target Cash Incentive Award

Metric	Value	Additional Details
Award Percentage	65% of Base Salary	Payout based on fiscal 2024 performance
Increase Over 2023	5% increase	Reflects enhanced performance expectations

Stock Options

Metric	Value	Additional Details
Grant Date	March 4, 2024
Exercise Price	$25.24	Based on closing price on grant date
Premium-Priced Option	87,271 shares at $27.76	110% of closing price on grant date
Vesting Schedule	25% at first anniversary, then 2.0833% monthly	Time-based vesting

Performance-Based Restricted Stock Units (PRSUs)

Metric	Value	Additional Details
Target PRSUs	35,000 shares	Target level at full achievement
Threshold PRSUs	17,500 shares (50% of target)	Minimum performance requirement
Maximum PRSUs	52,500 shares (150% of target)	Exceptional performance cap
Grant Date	March 4, 2024
Grant Date Stock Price	$25.24	Closing price on grant date
Grant Date Fair Value	$0	Conditions not probable for performance at grant date
Vesting Schedule	Vests after filing of FY-end 10-K (Dec 31, 2026)	Vesting contingent on achieving performance metrics
Evaluation Period	Through December 31, 2025	Performance metrics: software performance, Schr\u00f6dinger therapeutics group, and operating performance